OVCA1 inhibitors belong to a distinct and significant chemical class, primarily known for their remarkable ability to target and modulate the activity of the OVCA1 protein. This class of compounds exerts its inhibitory effects through specific interactions with the OVCA1 protein, leading to the suppression of its enzymatic function. OVCA1, also referred to as ovarian carcinoma antigen 1, is a crucial protein involved in several essential cellular processes, including cell proliferation, apoptosis, and DNA repair. The structural diversity of OVCA1 inhibitors is a defining characteristic of this chemical class. Chemical synthesis allows for the creation of diverse molecules with varying functionalities, enabling researchers to explore a wide range of potential inhibitors. The interaction between these inhibitors and the OVCA1 protein occurs via specific binding pockets or allosteric sites on the protein's surface. This binding interaction alters the conformation of the protein, leading to a loss of its enzymatic activity or disrupting its association with other cellular components.
Researchers have extensively studied OVCA1 inhibitors due to their potential implications in relation to cancer and other diseases associated with OVCA1 dysregulation. However, it is crucial to emphasize that this description solely focuses on the chemical class itself. To assess the efficacy and specificity of OVCA1 inhibitors, various studies and in vitro assays have been conducted. These investigations involve analyzing the inhibitory potency of different compounds against the OVCA1 protein while also evaluating their selectivity for this target. Understanding the structure-activity relationship of OVCA1 inhibitors is vital for optimizing their performance and minimizing off-target effects.Additionally, computational modeling and molecular docking techniques have played a pivotal role in predicting the binding modes of various OVCA1 inhibitors, thereby aiding the design and development of novel compounds with enhanced affinity and specificity for the OVCA1 protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
A tyrosine kinase inhibitor that targets VEGF receptor (VEGFR), Platelet-Derived Growth Factor Receptor (PDGFR), and others. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that targets several kinases, including Src family kinases. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
An mTOR (mammalian target of rapamycin) inhibitor that interferes with cell growth signaling pathways. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
Another PARP inhibitor studied for potential ovarian cancer research. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
A MEK inhibitor that targets the MAPK/ERK pathway. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
A multitargeted tyrosine kinase inhibitor that targets VEGFR2, c-MET, and AXL receptors, among others. | ||||||